P001: High-Throughput T-Cell Receptor (TCR) Engineering and Biophysical Analysis, Presented by Annie B., AbbVie, Inc.

P002: Developing Novel Human Antibodies for Innovative Diagnostics and Therapeutics, Presented by Jos R., AbSano BV

P003: A Human mAb Cocktail Combatting Most Common Variants of SARS-CoV-2, Presented by Simone W., AbSano BV

P004: Single-Chain Tandem Macrocyclic Peptides (STaMPs) as a Novel Multivalent Molecular Format, Presented by Kenichiro I., Ajinomoto Co., Inc.

P005: Introduction of 2nd Generation AJICAP® Technology- Expansion of Chemical Site-Specific Conjugation Capabilities, Presented by Yutaka M., Ajinomoto Co., Inc.

P006: Directed Evolution of an Enhanced-Affinity TACI Variant TNF Domain (vTD) Fc Fusion Protein, ALPN-303, Exhibiting Superior Inhibition of the B Cell Cytokines BAFF and APRIL, Presented by Daniel D., Alpine Immune Sciences, Inc.

P007: HCP Profiler: Reproducible Host Cell Proteins Identification and Quantification to Compare Different Batches, Presented by Hery R., Anaquant

P008: Antibodies Targeting Three Spike Protein Domains Regulating SARS-CoV-2 Infectivity, Presented by John K., Antibody Solutions

P009: APB-A1, a Novel Bispecific Anti-CD40L Antibody, Exhibits Therapeutic Efficacy in Collagen-Induced Arthritis Mouse Model by Blocking the CD40-CD40L Interaction, Presented by Susan C., AprilBio Co., Ltd.

P010: APB-R3, a Novel Immune Modulator Targeting IL-18, Mitigates the Severe Inflammatory Responses that Induced by Activated Macrophage, Presented by JongWook K., AprilBio Co., Ltd.

P011: CD79b Targeting ADC with Superior Pharmacokinetic Profile and Anti-Tumor Activity, Presented by Philipp S., Araris Biotech AG

P012: Antibody-Mediated Target Delivery of TLR7/8 Agonists, Presented by Siteng F., Binghamton University, State University of New York

P013: Usage of 6 Infinity Stones to Make an SPR Instrument? The Pro Series Instruments, Presented by Hniang K., Bruker Scientific LLC

P014: Production and Characterization of N- and C-Terminal Selenocysteine Proteins, Presented by Yogan K., Cayman Chemical

P015: In Vitro Efficacy Studies to Support Engineered T Cell Therapies, Presented by Marco G., Charles River Laboratories

P016: Humabody® V[H]: A Versatile Platform for Generation of Novel Therapeutics, Presented by Laurie G., Crescendo Biologics

P017: Delaying Tumor Growth Through Anti-Neuropilin-1 Antibodies Which Bind to Novel Epitopes, Presented by Eric Z., Cygnal Therapeutics

P018: Scalable Production of Griffithsin, a Broad-Spectrum Antiviral Protein and Anti-COVID-19 Candidate, Presented by John D., Duke University

P019: Two-Stage Dynamic Control Over Redox State Improves Cytosolic Expression of Disulfide Containing Proteins in E. coli, Presented by Jennifer H., Duke University

P020: Making Healthcare Accessible and Affordable to Patients Globally Through the Adoption and Use of an Engineered Eukaryotic Filamentous Fungal Cell Line, C1, that Markedly Improves Protein Yields and Lowers the Cost of Manufacturing Biologic Vaccines, Presented by Mark E., Dyadic International, Inc.

P021: Using Extrinsic Fluorescent Probe Bis-ANS to Measure Protein Surface Hydrophobicity, Presented by Wei W., Eli Lilly and Company

P022: Fabs-in-Tandem Bispecific T-Cell Engager for Efficient Tumor Killing and Minimal Cytokine Release, Presented by Danqing W., EpimAb Biotherapeutics

P023: Quantify Diverse Immune Cell-Mediated Killing Mechanisms: Applications of a Robust, Non-Radioactive KILR Cytotoxicity Platform, Presented by Jane L., Eurofins DiscoverX

P024: Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors, Presented by Alpana P., Eurofins DiscoverX

P025: Engineered E. coli with an Oxidative Cytoplasm and Efficient Cleavage of N-Terminal Methionine, Presented by Andrew L., Fina Biosolutions LLC

P026: FLT201: An Investigational Gene Therapy for Gaucher Disease Type 1 Utilizing an Engineered GCase Protein to Target Difficult-to-Reach Tissues, Presented by Fabrizio C., Freeline Therapeutics

P027: Measurement of a Humanized Fab Molecule in Three Different Ocular Matrices Utilizing One Assay Method, Presented by Olinda D., Genentech, Inc.

P028: Complementary Methods to Characterize and Quantitate Intact Stability of Novel Drug Modalities Using Capillary Electrophoresis Western Blot and Affinity Capture Coupled to LC-MS, Presented by Gawon S., Genentech, Inc.

P029: Protein or Not? Advanced Subvisible Particle Characterization with Fluorescent ID, Presented by Bernardo C., Halo Labs

P030: Introducing the Aura CL for Cell and Gene Therapy Aggregation, Particle Analysis and ID, Presented by Bernardo C., Halo Labs

P031: Multivalency Transforms SARS-CoV-2 Antibodies into Ultrapotent Neutralizers, Presented by Edurne R., Hospital for Sick Children Research Institute

P032: Targeting of Tumor-Specific Peptide Antigens with Bispecific T Cell-Engaging Receptor (TCER) Molecules, Presented by Sebastian B., Immatics Biotechnologies GmbH

P033: Plate-Based Screening for Rapidly Quantifying Secreted Protein Expression out of Mammalian Cells, Presented by Kenneth L., Institute for Protein Innovation

P034: High-Throughput Methodologies to Assess Polyspecific-Reactivity in Synthetically Developed Monoclonal Antibodies, Presented by Roushu Z., Institute for Protein Innovation

P035: Evaluation of LigaTrap™ Resins in IMCStips® for the High-Throughput Purification of Immunoglobulins, Presented by Dana M., Integrated Micro-Chromatography Systems, Inc. (IMCS)

P036: Automated High Throughput Protein Purification > 5 mL Samples Using Affinity IMCStips®, Presented by Huey N., Integrated Micro-Chromatography Systems, Inc. (IMCS)

P037: A Novel Method of High-Sensitive HOS Assessment and Thermal Stability Evaluation of Anti-SARS-CoV-2 Antibody Using Circular Dichroism Spectrometer, Presented by Satoko S., JASCO Corporation

P038: BhTS (Barcoded HTS) Platform to Improve Productivity of Biopharmaceuticals using 1200 Human Secretory Signal Peptides, Presented by Ji Hoon P., KBIO Osong Medical Innovation Foundation

P039: Multi-Omics Analysis for Characterization of Extracellular Vesicle, Presented by Ju Rang W., KBIO Osong Medical Innovation Foundation

P040: Calculation of Therapeutic Antibody Viscosity with Coarse-Grained Models, Hydrodynamic Calculations and Machine Learning-Based Parameters, Presented by Pin-Kuang L., Massachusetts Institute of Technology

P041: A Sequential Intact Mass - PRM Workflow to Characterize In Vivo Clipping of Novel Biologics by LC-MS: Cytokine-Fc Biotransformation Case Study, Presented by Xibei D., Merck & Co., Inc.

P042: A Novel Approach for Identifying Acid Dissociation Conditions to Support Immunogenicity Assay Development, Presented by Krisna D., Merck & Co., Inc.

P043: High-Throughput IgG Quantitation Platform for Clone Screening During Drug Discovery and Development, Presented by Cathy O., Molecular Devices LLC

P044: Directed Evolution of Non-Immunoglobulin Scaffold Proteins Against a Cancer Marker, Presented by Tiffany N., National Institute of Advanced Industrial Science and Technology (AIST)

P045: Engineering of Skin-Targeting Bispecific Antibodies that Drive Localized Immune Modulation in Autoimmune and Inflammatory Diseases, Presented by Susmita B., Pandion Therapeutics, Inc.

P046: Automated Plasmid Prep and Optimized Protein Separation Using PhyTip® Columns, Presented by Shadie N., PhyNexus, now part of Biotage

P047: Improving Transient CHO and HEK-293 Expression Systems with a Powerful Transfection Solution for High Protein Production Yields: FectoPRO®, Presented by Brian B., Polyplus-transfection

P048: Quantitative Cell-Based Reporter Gene Bioassays to Advance Individual or Combination Cancer Immunotherapy, Presented by Alissa K., Promega Corporation

P049: A Homogenous PBMC ADCC Bioassay Enables Bridging Studies with ADCC Reporter Bioassays in Immunotherapy Monoclonal Antibody Development, Presented by Jeff N., Promega Corporation

P050: Novel Bioluminescent Bioassays for the Discovery and Development of Molecular and Cellular T-Cell Redirecting Cancer Therapy, Presented by Brad S., Promega Corporation

P051: Simplifying AAV Analytics with Maurice, Presented by Chris H., ProteinSimple, a Bio-Techne Brand

P052: Concentrating on AAV Impurities with Ultrasensitive Total Protein Detection on Simple Western, Presented by Chris H., ProteinSimple, a Bio-Techne Brand

P053: Protein Production, Biochemical and Biophysical Characterization as Well as X-Ray Crystallography and Cryo-EM for Biologicals During Early Drug Discovery, Presented by Brantley H., Proteros USA, Inc.

P054: Cell-Tethered IL-12 Improves Anti-Tumor Efficacy of Adoptive T Cell Therapy, Presented by Jonathan N., Repertoire Immune Medicines

P055: Identifying Specific Cell Surface Heterodimer Receptors and Off-Targets: Integrin and CD3 Receptor Examples, Presented by Nick B., Retrogenix Ltd.

P056: From Sample to Report: Automating MS Analytics of Next-Generation Protein Therapeutics, Presented by Miroslav N., Roche Diagnostics GmbH

P057: Rational Engineering of Polysaccharide-Degrading Enzymes: A Case Study on Cellulases, Presented by Bhargava N., Rutgers University

P058: Development of Potent and Effective SARS-CoV-2 Nanobodies, Presented by Maxwell S., Sandia National Laboratories

P059: Fine Tuning of the Temperature in Sodium Dodecyl Sulfate Capillary Gel Electrophoresis (CE-SDS) for Better Separation Resolution of New Biopharmaceutical Modalities, Presented by Steven C., SCIEX

P060: From Peptides to Intact Mass Analysis: A Flexible Solution for Monitoring Multiple Attributes, Presented by Hans D., SCIEX

P061: Generation of Functional Monoclonal Antibodies by Single B Cell Cloning, Presented by Jiahui Y., Sino Biological US, Inc.

P062: Characterization of a Reporter Gene Cell Line for the Easy Assessment of Therapeutic AAV Vectors – A Case Study, Presented by Therese S., Svar Life Science AB

P063: Selected Regulatory Elements to Enhance the Efficacy of mRNA Vaccines, Presented by Beate S., UniTargetingResearch AS

P064: Development of a Highly Specific Antibody Drug Conjugates for Non-Hodgkin's Lymphoma Treatment, Presented by Ana A., Universidade de Lisboa

P065: A Simplified Workflow for Monoclonal Antibody Sequencing, Presented by Lena M., University of California, Santa Cruz

P066: Using Blender as a Site-Specific 3D Glycoprotein Visualization Software to Create Accurate and Visually Appealing Glycoprotein Renderings, Presented by Daniel R., University of Georgia

P067: Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC in the Multiple Myeloma Context, Presented by Margaux L., University of Liege

P068: B7-H3/CD16 Bispecific Killer Cell Engagers for Therapy of Non-Small Lung Cell Cancer, Presented by Qi Z., University of Macau

P069: Engineering Cell-Based Selections for Translatable Ligand Discovery, Presented by Patrick L., University of Minnesota - Twin Cities

P070: Potency Enhancement of HIV-1 Neutralizing Antibodies by Site-Specific Chemical Modification, Presented by Sara I., University of the Basque Country

P071: Focal Accumulation of Aromaticity at the CDRH3 Loop Mitigates 4E10 Polyreactivity Without Altering Its HIV Neutralization Profile, Presented by Izaskun M., University of the Basque Country

P072: Nanomolar Protein-Probe Antibody Aggregation Assay, Presented by Harri H., University of Turku

P073: Engineering Antibodies to Trigger BAK-Mediated Apoptosis in Cancer, Presented by Hema S., Walter and Eliza Hall Institute of Medical Research

P074: In Silico Screening of PET-Degrading Enzymes, Presented by Marina C., ZYMVOL Biomodeling SL

P075: Optimization of ÄKTA Pure Automation to Improve Efficiency and Recovery of Antibodies Produced at Research ScalePresented by Jane G., Sanofi US

P076: Generation of Natural and Fully Human Antibodies for Therapeutic Applications, Presented by Jonas K., YuMab GmbH

P077: Development of In Vivo Anti-CD19 CAR T-Cell Therapy Based on Hybrid Nanoparticles, Presented by Cécile B., Ixaka France

P078: Generation of Bispecific and Trispecific T Cell Engagers (TCEs) and NK Cell Engagers (NKEs) Without Prior IgG Reengineering, Presented by Floris V., SynAffix BV

P079: ProTECT™, a Novel Antibody Platform for Integrating Tumor-Specific Immune Modulation and Enhancing the Therapeutic Window of Targeted Multispecific BiologicsPresented by Meghan V., Zymeworks, Inc.

P080: Designing an Affinity Maturation Library for Trastuzumab, Presented by James M., Fusion Antibodies

P081: Comprehensive Characterization of Multi-Specific Therapeutics Using Peptide Mapping and Subunit Analysis, Presented by Matthew S., SCIEX

P082: Photo-Crosslinking of Recombinant Protein Vesicles via Incorporation of Unnatural Amino Acids, Presented by Yirui L., Georgia Institute of Technology

P083: Function First: Identification of Synergistic Multi-Antibody Cocktails with Broad Epitope Coverage of SARS-CoV-2 Spike Protein from Complementary Antibody Discovery Platforms, Presented by Yasmina A., ImmunoPrecise Antibodies